drugset / Trial / NCT07517510
HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).
Phase 2
Enrolling by invitation
40 enrolled
Guangdong Second Provincial General Hospital
Dongguan People's Hospital · collabFirst Affiliated Hospital of Guangxi Medical University · collabGuangzhou First People's Hospital · collabNanfang Hospital, Southern Medical University · collabShenzhen Second People's Hospital · collabSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collabZhongshan People's Hospital, Guangdong, China · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the safety and efficacy of homoharringtonine combined with venetoclax and azacitidine regimen (HVA) in newly diagnosed MPAL patients, providing a basis for the use of the HVA regimen in the treatment of MPAL.
Timeline
- Start
- 2026-04-01
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Homoharringtonine | Small molecule | 1 mg/m2 | Intravenous |
| Subject | Venetoclax | Small molecule | 400 mg | — |